show increas spend vadadustat
enrol continu initi cost hit
updat ep well estim
spend much higher across board vs
estimate addit phase enrol new studi
vadadustat hit sg vs estimate cost
upcom merger begin bite lower ep estim
result akebia keryx biopharmaceut kerx rate recent
announc merger expect close yearend keryx
renal disease-focus compani commerci approv auryxia
ferric citrat us via market organ auryxia
oral phosphat binder also first fda-approv oral iron
medicin specif develop treat iron defici anemia non-
dialysi ckd patient auryxia first approv septemb
control serum phosphoru level ckd patient dialysi label
expand novemb includ iron defici anemia non-
dialysi ckd patient growth pick keryx report
us auryxia sale vs yr/yr estim us
peak revenu keryx provid akebia effici way
establish us sale effort vadadustat complet
vadadustat materi promis vadadustat improv maintain
hemoglobin hb erythropoietin epo level dialysis-
depend non-dialysi renal anemia patient standard-of-car
esa rais epo level well beyond normal level associ
increas cardiovascular vadadustat bolster hb modest
epo rise increas vegf drug interact
vadadustat signific global opportun deal otsuka vifor
mitsubishi tanab total potenti valu includ
fund along royalti profit split vadadustat
look rapidli penetr dialysi market expand use non-
dialysi patient estim exceed revenu peak
approv readout expect reach
valuat addit keyrx approv grow auryxia sg
effici gain off-set increas dilut keep price target
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
overview pend merger transact keryx
keryx
biopharmaceut announc definit merger agreement combin
two compani all-stock transact merg compani
name merger unanim approv
board director compani keryx largest sharehold
baupost group own outstand kerx share prior
agre convers million zero coupon senior convert note
held baupost enter vote agreement support transact
merger expect close end subject sharehold approv
compani customari close condit includ anti-trust
term all-stock merger keryx sharehold receiv
common share kerx share impli equiti ownership new
akebia akebia sharehold keryx sharehold
fulli dilut basi pro-forma merg entiti would million
cash base june cash balanc manag expect
recogn million cost synergi within year princip relat
new akebia manag structur led akebia execut john butler
akebia presid ceo would lead combin compani ceo
jason amello akebia cfo expect serv similar capac
merg compani new akebia board akebia
keryx keryx nomin chairperson
keryx brief keryx boston-bas kidney diseas compani focus
commerci product auryxia ferric citrat us
person us sale forc manag market organ auryxia first
approv fda septemb control serum phosphoru level
ckd patient dialysi novemb treatment iron
defici anemia non-dialysi ckd patient auryxia non-calcium
oral phosphat binder first fda-approv oral iron medicin
specif develop treat iron defici anemia non-dialysi ckd
nephrologist associ dialysi center regard market potenti
keryx estim dialysi patient current
phosphat binder million non-dialysi patient care
nephrologist ckd includ treat
keryx/auryxia recent perform keryx end cash
million compani report us auryxia net sale vs
yr/yr sale vs
oper cash burn approxim
addit keryx report us auryxia net sale
annual report auryxia us sale
respect
akebia background/summari akebia
cambridg
massachusett focus deliv innov therapi patient
applic hypoxia-induc factor hif biolog akebia lead
candid vadadustat once-daili oral hif prolyl hydroxylas
hif-ph inhibitor treatment renal anemia low blood oxygen
vadadustat activ via inhibit hif-rel prolyl hydroxylas
enzym promot breakdown hif protein enabl
bodi cell adapt low oxygen level treatment anemia
enhanc hif activ vadadustat offer opportun
comprehens physiolog respons anemia standard-of-car
erythropoietin epo supraphysiolog level result associ
increas cardiovascular risk use renal anemia patient limit
result vadadustat abl effect elev maintain hemoglobin
hb appropri level bolster epo modestli normal
physiolog level phase vadadustat rais maintain good
hemoglobin control dialysis-depend non-dialysi depend
renal anemia patient vadadustat may therefor offer conveni oral
once-daili potenti safer altern esa current achiev
billion annual revenu vadadustat midst expans global phase
studi readout expect late potenti global
approv bolster presenc global akebia enter
multipl develop market agreement otsuka otski
rate mitsubishi tanab mtzxf rate vifor pharma vifn
rate vadadustat collabor total billion
potenti valu includ million up-front payment develop
fund well high royalti profit split depend specif
deal due high burden morbid mortal face chronic kidney
diseas patient renal anemia due potenti profil estim
vadadustat could exceed billion peak global revenu addit hif
stabil develop akebia consid indic
inflammatori bowel diseas among other
exhibit renal anemia caus chronic kidney diseas ckd lead
reduc level epo red blood cell oxygen
renal anemia common even earli chronic kidney diseas ckd
nearli million peopl us suffer chronic kidney diseas
estim million patient also suffer anemia accord
akebia other almost everyon end stage renal diseas esrd
stage anemia kidney produc erythropoietin epo help
regul bodi function red blood cell product bone
marrow import carri oxygen throughout bodi chronic
kidney diseas anemia gener aris kidney failur produc
adequ amount erythropoietin due progress loss kidney function
result reduc number red blood cell low hemoglobin level
reduc oxygen level bodi exhibit patient renal anemia
experi symptom includ fatigu decreas cognit mental
acuiti sleep disturb increas risk hospit prolong
hospit length stay among other renal anemia also associ
heart complic left ventricular hypertrophi congest heart
failur due hypoxia increas heart strain exampl
increas left ventricular dilat may occur decreas mg/dl
hemoglobin level left ventricular hypertrophi may develop patient
hb level low mg/dl
current standard renal anemia associ increas
cardiovascular risk treatment renal anemia anemia
materi revolution fda approv genet engin form
erythropoietin epo relat analogu refer
erythropoiesi stimul agent esa commonli use esa
us epogen epoietin alfa aranesp darbepoietin alfa mircera
methoxi polyethylen glycol-epoetin beta treatment esa result
rais hb also epo level materi physiolog level
abnorm high epo level associ increas cardiovascular
advers event exhibit materi limit restrict use
despit benefici effect esa reduc import symptom
anemia help ultim creat billion global esa market
peak treat renal anemia patient agent may increas patient
risk heart attack stroke limit use
relat
dramatic-
result
much
renal anemia treatment vadadustat potenti offer
conveni complete/eleg potenti safer altern
treatment anemia inject esa associ increas
cardiovascular risk vadadustat oral small molecul stabil
permit broad-bas activ hypoxia-induc factor hif
transcript factor employ bodi presenc hypoxia
low oxygen hif oxygen-sensit compon hif constantli
synthes though presenc normal oxygen hif degrad
inhibit activ directli inhibit prolyl hydroxylas domain-
contain enzym ph phd integr part hifdegrad
vadadustat achiev enhanc hif activ signal result
increas product epo hemoglobin iron mobil along
effect exhibit importantli epo elev seen vadadustat
anywher near level seen esa rather approxim
normal physiolog level exhibit also importantli along increas
epo product iron uptak util also posit affect
increas hif activ could lead reduct need iron
supplement well safeti benefit last hif stabil
report stimul hematopoiesi via pathway independ epo
provid anoth pathway increas hb beyond esa collect
enhanc hif signal repres complet broad-bas respons
anemia achiev inject esa alon creat opportun
vadadustat becom materi altern esa renal anemia
mobil stabil hypoxia-induc factor transcript factor
mimic
respons
seen high
akebia corpor pre april adapt bighman gene dev
multipl mechan -- increas product epo hemoglobin
iron mobil among other -- hif stabil activ
vadadustat may offer attract altern esa earli studi
vadadustat increas hemoglobin restor normal physiolog level
epo allow gradual well-control hemoglobin respons exhibit
phase studi vadadustat rais maintain hemoglobin level
dialysis-depend non-dialysi depend renal anemia patient
primari efficaci endpoint phase studi addit hif-ph inhibitor
also develop renal anemia includ roxadustat
rate daprodustat glaxosmithklin gsk rate
import differenti characterist vadadustat among hif-ph
inhibitor develop depend upon compar shorter
half-lif appropri mimic physiolog epo fluctuat
stabil elev hemoglobin level within target rang lower
elev epo though head-to-head studi appear
induc chang vegf level minim potenti drug
interact statin believ element import
patient physician consid molecul believ creat
potenti vadadustat becom class leader among hif-ph inhibitor
major vadadustat clinic readout expect begin late
result vadadustat larg phase program expect late
studi examin vadadustat
non-dialysi patient anemia relat ckd ndd-ckd expect
result depend upon event rate trial
phase program assess vadadustat dialysi
patient anemia relat ckd dd-ckd also expect read
late studi aranesp compar includ
two separ patient group correct group evalu patient
current treat esa convers group evalu patient
current receiv esa convert either vadadustat activ
control primari efficaci endpoint phase studi chang
hemoglobin hb baselin primari safeti endpoint
incid mace major advers cardiovascular event addit
vadadustat result esa hyporespond also expect
pivot phase meaning
vadadustat deal otsuka mitsubishi tanab valid develop
vadadustat effici yet maintain materi portion econom
akebia ink seri collabor two materi collabor
otsuka us cost-shar deal develop commerci
vadadustat includ profit split renal market
second tradit licens collabor eu china territori
also collabor mitsubishi tanab pharma
develop commerci vadadustat japan taiwan south
korea indonesia india countri asia three collabor
vadadustat togeth total billion potenti valu
includ million up-front payment potenti develop
fund believ size scale deal provid materi valid
vadadustat potenti renal anemia market
canni vifor deal provid enhanc us dialysi market access us
akebia also enter exclus agreement vifor pharma
exclus provid vadadustat freseniu medic dialysi unit
center treat dialysi patient total us dialysi
patient vifor deal gener million equiti akebia along
million mileston payment profit share arrang
akebia vifor akebia receiv vast major profit
importantli believ arrang provid vehicl
result vadadustat rapid access dialysi market us hif-
pd inhibitor molecul ad reimburs bundl
akebia assum bundl exampl rapid penetr
dialysi market demonstr rapid adopt mircera pegyl
epoetin beta dialysi market sign deal vifor
deal
result
market
exhibit access larg dialysi organ influenc util
vadadustat blockbust potenti accord akebia approxim
patient us suffer anemia relat chronic kidney diseas
includ dialysi patient world-wide esa market repres
opportun us repres eu
countri repres total market due high burden
morbid mortal face chronic kidney diseas patient once-
daili oral conveni well potenti improv hemoglobin
control better iron mobil possibl improv safeti expand
market even vadadustat arriv second hif-hd inhibitor market
estim vadadustat global revenu potenti could exceed billion
chronic kidney diseas potenti indic ad beyond
 hemoglobin hb gener well-manag target rang
 solid earli phase data ndd- dd-ckd patient
 lower hepcidin potenti reduc iv/or iron supplement
 potenti reduc cardiovascular vs inject esa
 interact statin chang plasma vegf level
 dose once-daili non-dialysi three-tim weekli dialysi patient
 import us dialysi market access agreement vifor pharma
akebia manag strategi akebia savvi manag team led
ceo john butler abl employ strategi effici thread
needl regard vadadustat develop term abl
financ robust vadadustat clinic program time abl
maintain materi econom akebia akebia team effect four major
deal eighteen month cover globe yet maintain import
commerci capabl akebia us beyond vadadustat akebia
licens librari hif product candid intend develop
indic expect add valu time specif
also develop inflammatori bowel diseas
form anemia
new akebia valuat number signific event expect
come quarter year give akebia potenti high earn
variabl employ sum-of-the-part net present valu npv
methodolog valu oper employ risk-weight fully-tax
valuat methodolog calcul new akebia asset includ
announc merger keryx new akebia npv appear larg
depend upon late-stag therapi vadadustat calcul
penetr oral comprehens therapeut believ
exceed billion global auryxia keryx commerci
phosphat binder new akebia program cash equival
nol credit less corpor overhead neg
yield total per share exhibit basic assumpt includ
fulli tax figur share count million share upon complet
merger
exhibit npv estim new akebia share
vadadustat increas product erythropoietin produc dose-
depend increas erythropoietin reticulocyt once-daili dose
vadadustat support result phase clinic studi
respect show vadadustat safe well-toler million
seri financ allow initi phase
million seri financ proce
million seri financ allow akebia complet two phase studi
posit program pivot studi proce
million seri financ use fund continu develop akb-
next month
akebia ipo rais million march akebia announc
price initi public offer share common stock
per share aggreg net proce approxim million
fund continu develop vadadustat
new akebia asset npvaluenpv/sharevadadustat anemia pipelin credit akebia
exhibit prior materi event akebia vadadustat
phase data vadadustat non-dialysi ckd patient
studi result present intern societi nephrolog world
congress nephrolog demonstr vadadustat control hemoglobin
level sustain clinic relev manner produc coordin
physiolog respons anemia hemoglobin measur
treat patient within clinic relev rang g/dl
vadadustat also restor physiolog level iron mobil
phase data show stabl hemoglobin level non-dialysi ckd
patient convert esa vadadustat studi present
european renal association-european dialysi transplant associ
era-edta show group patient convert activ esa
therapi vadadustat maintain mean baselin hemoglobin level
throughout studi wherea patient switch placebo
declin hemoglobin mean within first two
week random result support start dose mg
daili patient convert esa vadadustat
posit phase data vadadustat vadadustat met
primari endpoint maintain stabl hemoglobin level week
treatment three cohort patient mg daili mg daili three-
time weekli patient cover esa vadadustat
studi design evalu abil vadadustat maintain
hemoglobin level hemodialysi patient previous treat esa
mitsubishi agreement vadadustat japan asia ex-china
mitsubishi make payment total million cost associ
global phase program vadadustat includ million paid
million million receiv use fund local
develop vadadustat japan akebia also elig receiv
approxim million develop sale mileston receiv
tier royalti payment low teen sale vadadustat
japan taiwan south korea indonesia india asian countri
vadadustat move phase vadadustat seri dealposit data total mm financ million seri financingto complet studi million seri financingproce fund vada develop ipo share net proce vadadustat data vadadustat announcedallow program proceed tanab deal vadadustat japanpay includ win eu patent disputepreserv access eu program initiatedvadadustat non-dialysi patient program initiatedvadadustat potenti anemia chronic kidney publish kidney intldata provid strong foundat agreement vadadustat uspay akebia could exceed licens hif portfolio jacceler strategi dev hif-target publish nephrolpubl provid strong basi agreement vadadustat eu china maxim payment otsuka deal vadadustat us dialysi market deal involv equiti stake exclus vadadustat hyporespond studi initiatesdata expect import group secondari offer fund vadadustat develop vadadustat japan studi top-line datados studi move studi japanuuu import rate least import uuuuu import
phase program initi non-dialysi ckd patient
first global phase program evalu vadadustat non-
dialysi patient anemia relat chronic diseas ndd-ckd
studi evalu patient current treat esa
studi evalu patient current receiv esa
convert either vadadustat activ control goal
maintain baselin hemoglobin level enrol
ndd-ckd patient across site global design support
registr chronic kidney diseas ckd patient activ compar
aranesp primari efficaci endpoint chang hemoglobin
baselin primari safeti endpoint mace event top-line data
expect
european patent offic epo revok european patent ep
patent entireti confirm none patent
claim met requir patent revok patent
entireti believ decis preserv vadadustat access
vadadustat show lack signific drug-drug interact
studi present european renal association-european dialysi
transplant associ era-edta demonstr vadadustat
clinic signific interact substrat involv
metabol mani commonli prescrib medic cholesterol
blood pressur medic suggest dose modif
necessari vadadustat
prescrib commonli prescrib
public highlight greater mortal esa hyporespond
analysi patient publish american journal
kidney diseas result indic dialysis-depend ckd patient
hyporespond erythropoiesi stimul agent greater
fold risk mortal requir higher dose esa iron
posit phase vadadustat ndd-ckd patient publish
studi publish pergola et al kidney intern conclud
vadadustat increas maintain hemoglobin level non-dialysi
depend ckd patient studi predict
control manner primari endpoint percentag patient
last week treatment achiev maintain either mean
hemoglobin level g/dl mean increas hemoglobin
g/dl redos averag significantli primari endpoint
met patient vadadustat patient placebo
signific increas reticulocyt total iron bind
capac signific decreas serum hepcidin ferritin level
observ patient take vadadustat compar placebo
result provid strong foundat vadadustat global phase
treat
public studi highlight benefit hif treatment
renal anemia studi publish journal nephrolog
conclud higher altitud associ higher hemoglobin level
lower mortal even lower use erythropoiesi stimul agent iv
iron studi demonstr treatment mimic effect high
altitud like hif stabil may benefici renal anemia patient
phase program initi dialysis-depend ckd
patient phase program design assess
vadadustat potenti dialysi patient anemia relat chronic kidney
diseas includ two separ studi studi
evalu patient current
erythropoiesi stimul agent esa
studi evalu patient current receiv esa convert
either vadadustat activ control goal maintain
baselin hemoglobin level primari endpoint includ mean chang
hemoglobin baselin primari evalu period
assess cardiovascular safeti measur standard major advers
cardiovascular event mace criteria top-line data expect late
us profit-shar deal otsuka vadadustat akebia
otsuka agre share cost develop commerci
vadadustat us well profit potenti futur sale
vadadustat renal market akebia could receiv million commit
fund plu develop commerci mileston million total
transact could exceed billion akebia receiv payment
million up-front million payment expect receiv
million cost phase global program otsuka
sale forc us proven track record drive
success launch collabor ensur vadadustat
necessari resourc success launch us approv fda
akebia licens hif portfolio addit indic
johnson johnson akebia sign agreement johnson johnson
review licens extens librari hif product candid
potenti applic across multipl therapeut area deal includ
world-wide right non-or absorb preclin molecul
inflammatori bowel diseas ibd allow potenti clinic
develop well expans pipelin includ
product compani portfolio term multi-year research
agreement akebia pay million cash arm
option take ownership interest issuanc
warrant exercis million anytim five year
vadadustat phase public american journal nephrolog
random double-blind phase trial martin et al evalu
pharmacodynam respons safeti toler vadadustat patient
random one five dose group mg vadadustat
placebo week studi demonstr non-dialysi ckd stage
patient vadadustat increas hemoglobin level dose-depend
manner
iron mobil compar placebo
public demonstr vadadustat potenti provid strong basi
phase program
eu china deal otsuka vadadustat akebia otsuka
announc expand collabor vadadustat
enter separ license/collabor agreement eu china
territori akebia receiv total transact valu approxim
million consist million up-front million commit
capit million develop fund million
mileston payment akebia also receiv tier double-digit royalti
payment sale vadadustat otsuka territori includ
europ russia china canada australia middl east
akebia vifor pharma sign deal provid vadadustat
freseniu medic akebia vifor pharma announc
enter agreement sell vadadustat freseniu medic
dialysi clinic us upon fda approv term agreement
vifor pharma distribut vadadustat freseniu medic center use
dialysi patient total us dialysi patient vifor pharma
expect make equiti invest akebia per share deal
still subject vadadustat approv fda inclus vadadustat
bundl reimburs model akebia may receiv million
payment vifor revenu vifor/akebia profit share come
akebia still split akebia otsuka
akebia prevail addit eu patent opposit
divis od european patent offic revok anoth hif-
relat patent europ patent patent challeng result
significantli narrow claim cover indic
akebia intend develop vadadustat posit outcom
follow akebia success challeng two fibrogen european patent ep
ep revok entireti od
march decemb respect
vadadustat posit phase japanes non-dialysi ckd
patient phase studi design evalu vadadustat
japanes patient anemia associ ndd-ckd evalu
patient placebo-control fixed-dos period
activ treatment dose adjust mainten period primari
efficaci endpoint mean hb chang baselin week compar
vadadustat placebo signific
improv observ
vadadustat
compar placebo common report respiratori tract
infect hypertens seriou advers event consist
prior studi includ patient death report
collabor revenu mitsubishi tanab expect commenc
follow phase result mitsubishi respons cost
local phase studi japan make addit payment akebia
phase unless choos access data global phase
studi later date
jan vadadustat posit phase japanes dialysis-depend
ckd patient phase studi design evalu vadadustat
japanes patient anemia associ dialysis-depend ckd
evalu patient placebo-control fixed-dos period
activ treatment dose adjust mainten period
primari efficaci endpoint mean hb chang baselin week
compar vadadustat placebo signific improv observ
vadadustat
compar placebo common report
masopharyngityi diarrhea headach seriou advers
event consist prior studi includ patient
exhibit potenti upcom import catalyst akebia
phase vadadustat studi dialysis/hyporespond
restart studi design assess vadadustat
dialysis-depend patient respond esa use
esa increas risk morbid mortal akebia
partner fine-tun studi maxim breadth
appeal vadadustat upon launch increas type patient
includ broader set dialysi patient addit
hyporespons also includ once-daili well weekli dose
patient switch daili weekli dose week data
expect could provid meaning differenti
vadadustat use patient util much greater epo
materi wors outcom studi random open-label studi
assess safeti efficaci vadadustat versu activ compar
epoetin alfa approxim patient us primari outcom
measur percent reduct previous prescrib epoetin alfa dose
chang hemoglobin level cours studi studi help
establish util molecul popul high unmet need data
revis studi expect around
ind file inflammatori bowel diseas ibd pre-clin
endoscopi result diseas model ulcer coliti
encourag attract compound non-absorb
thu potenti avoid unwant system effect potenti
associ hif-ph inhibit well potenti interact
repres next indic beyond renal anemia akebia plan
target hif compound
on-going preclin studiesdata determin go/no go decis vada revis hyporespond studi initiatesdata expect late import group ind file inflammatori boweldata reconfirm posit preclin resultsuul vadadustat switch studi initiatesdata expect multipl comparatorsuuul enrol complet vadadustat registr studi phase data ibddriv studi hif use beyond top line vadadustat hyporespond studydata show activ challeng patientsuuuul top line dialysis-ckd data efficaci chg hb result driven mace top line non-dialysis-ckd data chg hb result driven mace file vadadustat ckd dd ndd registr studi vadadustat switch studydata reinforc potenti switch vs esa approv vadadustat ckd dd ndd base registr studi rate least import uuuuu import
late complet enrol vadadustat larg pivot
studi chronic kidney diseas program non-dialysi
evalu patient current treat esa
convers studi evalu patient current receiv esa
convert either vadadustat activ control arenesp goal
maintain baselin hemoglobin level program
studi evalu patient current treat esa
studi evalu patient current receiv esa
convert either vadadustat activ control goal
maintain baselin hemoglobin level activ compar aranesp
primari efficaci endpoint chang hemoglobin baselin
primari safeti endpoint mace event
late initi phase vadadustat switch studi
updat design dialysi patient phase studi design
modifi earli expect enrol approxim dialysis-
depend patient begin late data
expect time approv earli dialysi patient typic
receiv treatment three time week three-tim weekli dose arm
vadadustat design examin vadadustat administr day
dialysi hemodialysi shown signific impact
pharmacokinet vadadustat therefor vadadustat could
administ safe along dialysi session phase result three-
time weekli dose posit akebia also also includ once-daili
dose examin vadadustat switch multipl esa epogen
aranesp mircera order inform physician switch esa
across widest rang patient
result increas iron mobil well broader hif-rel
signal vadadustat may allow robust comprehens
consist hemoglobin respons hyporespond patient akebia
partner fine-tun studi maxim breadth
appeal vadadustat upon launch increas type patient
includ broader group dialysi patient addit
hyporespons akebia also includ once-daili well
weekli dose patient switch daili weekli dose
week data expect could provid meaning
differenti vadadustat use patient util much greater
epo materi wors outcom
phase data inflammatori bowel diseas repres
next indic beyond renal anemia akebia plan target
hif compound posit phase data support develop
late top-lin phase result dialysis-
includ two separ group two separ studi
correct studi evalu patient current treat esa
studi evalu patient current receiv esa
convert either vadadustat activ control goal
maintain baselin hemoglobin level activ compar
aranesp primari efficaci endpoint chang hemoglobin
baselin primari safeti endpoint mace event time
program driven mace event trial continu
enrol patient could complet around yearend
earli independ data monitor committe met
recommend continu studi without chang
top-lin phase result non-dialysis-
separ group two separ studi studi
evalu patient current treat esa
convers studi evalu patient current receiv esa
convert either vadadustat activ control goal
maintain baselin hemoglobin level enrol
ndd-ckd patient across site global design support
registr chronic kidney diseas ckd patient activ compar
aranesp primari efficaci endpoint chang hemoglobin
baselin primari safeti endpoint mace event time
readout program driven mace event trial
continu enrol enrol goe well enrol cap patient
independ data monitor committe met
recommend continu studi without chang
highli conveni once-daili three-tim weekli oral dose
vadadustat achiev hemoglobin increas stabil epo
elev much moder well esa vadadustat
therefor potenti offer conveni complet
potenti safer treatment renal anemia believ
attract altern inject esa associ increas
cardiovascular risk vadadustat also minim drug-drug interact
materi impact metabol statin commonli prescrib
ckd patient importantli akebia also struck major deal
signific partner across globe provid access dialysi
market us market heft non-dialysi ckd anemia market
upon approv estim project rel rapid penetr
dialysis-depend market us follow market penetr
market expans treatment util larg untap non-dialysi
patient group exhibit assum price slight premium
current esa us per annum non-dialysi
given overal efficaci toler profil
vadadustat believ paramet lead revenu estim
exceed billion global exhibit use discount reflect risk
success phase global approv estim vadadustat program
current risk-weight fully-tax npv per share new akebia
exhibit vadadustat us revenu build-up anemia associ chronic kidney diseas
w/renal anemia w/ndd-ckd w/dd-ckd ndd-ckd treat dd-ckd treat ndd-ckd treat dd-ckd treat non ndd-ckd treated- number dd-ckd treated- total day ndd-ckd therapy- total day dd-ckd therapy- non-dialysi price/day launch price full dialysi price/day launch price full estim ndd-ckd us revenue- estim dd-ckd us revenue- total us revenue-
exhibit vadadustat npv akebia vadadustat use anemia associ chronic kidney diseas
 total revenue- us revenue- dialysi vifor non-dialysis- eu/chinarevenu otsuka japanese/asia revenu mtpc cogs- cog econom payment- vifor royalti total sg us total us expenses- us l- us econom otsuka upfront- us profit split reimburs us mileston dev reg com- total us profit loss eu/row licens otsuka upfront- reimbursemt fom eu/china mileston dev reg com- royalti dd amt- eu/intl profit japan/asia licens mtpc up-front data access reimburs japan/asia mileston dev reg com- royalti rate mid-teen amt- jap/asia profit total econom effect tax eff valuat pivot result total value/mergeco total valu value/mergeco
regulatory/fda compani whose main busi
drug
develop akebia subject strenuou regulatori requir
fda intern regulatori agenc new drug
approv promot approv drug product also sternli regul
fda relat agenc throughout globe also gener though
compani specif focu ethic prescript pharmaceut place
signific risk oper due fda government regulatori
bodi believ specif risk time greater
research-bas drug develop compani
manufactur risk fda recent vigil inspect
drug manufactur plant akebia could subject addit risk
type fda regard manufactur therapeut drug
submit licensur us approv meaning problem
akebia manufactur oper contract
accomplish goal could materi share
depend upon vadadustat progress success materi portion
akebia estim revenu cash profit estim come
develop vadadustat hif stabil develop anemia relat
chronic kidney diseas vadadustat demonstr signific
clinic benefit efficaci safeti suffici satisfi regulatori author
fda emea demonstr enough benefit convinc
payer provid care us government reimburs
agenc eu larg anticip potenti revenu cash profit
expect result approv risk could materi restrict
compani sever way like materi neg affect
depend upon benefici advanc hif-ph biolog renal
anemia patient materi portion akebia estim revenu cash
profit estim come develop vadadustat hif
stabil believ materi amount risk depend upon inhibit
hif-ph behav manner benefici develop vadadustat
renal anemia patient materi aspect sustain inhibit hif-ph
renal anemia patient remain elucid may determin
outcom larg pivot trial trial vadadustat
specif chronic suppress hif-ph may potenti lead
tumorgenesi patient understand may present materi
challeng develop regulatori commerci success
vadadustat hif-ph inhibitor patient renal anemia
intellectu properti risk multipl patent issu akebia
protect vadadustat multipl patent issu
potenti competitor hif-ph inhibitor space protect
hif-ph inhibitor therapeut roxadustat akebia expect issu
fibrogen us patent conflict intellectu properti awar
valid us patent issu claim method use
product candid purpos inhibit hif-ph treatment
anemia secondari ckd numer challeng broad
patent issu eu japan issu
us despit patent revok appeal decis
file though anticip success
challeng maintain re-establish patent intellectu properti
could ultim result limit vadadustat potenti region
could harm share
financ risk share may subject financ risk compani
may need rais addit capit prior complet vadadustat
program may need rais addit fund complet studi
hif target molecul pipelin indic
guarante addit financ circumst may
result sharehold absorb materi oner addit dilut
merger-rel risk share may subject risk associ
all-stock merger transact announc june combin akebia
keryx biopharmaceut transact unanim approv
board compani subject sharehold vote
transact expect close end transact fail
close propos complet oper larger
integr compani effect manag akebia oper could
neg affect share could trade neg
addit risk akebia incur expect incur signific cost
law regul relat corpor govern
matter akebia subject feder state foreign healthcar law
regul implement chang healthcar law
regul could advers affect busi result oper
akebia incom statement includ impact propos keryx merger
new akebia incom statement total revenue- us- akebia revenu vadadustat us profit share- total vadadustat royalty- otsuka eu/china/ royalty- mitusubishi tanab japan/asia royalty- total vadadustat milestones- otsuka us- otsuka eu/row- mtpc japan- total auryxia sales- net us auryxia sales- licens revenue- total collabor revenu total akebia revenue- expens cogs- total oper oper incom interest incom one-tim accret prefer incom pre-tax incom pre-tax taxes- tax ratenmnmnmnanmnmnmnmnananaoth comprehens comprehens incom comprehens fully-tax o/ fulli o/ inc sec file research estim contact inform robert hazlett manag director bitg
akebia balanc sheet flow includ impact propos keryx merger
cash avail sale receivable/unbil expens current total current equip defer offer costs- total stockhold equityaccount accru defer total current revenu net current non-curr total redeem convert prefer paid-in accumul comprehens incom stockhold total liabil stockhold akebia extinguish debt amort premium/discount dispos properti base fair valu warrant issu license- unbil receivable- prepaid expens current long-term account accru defer revenue- defer net cash provid oper activitiespurchas matur avail sale avail sale cash provid invest activitiesproce issuanc common issuanc prefer exercis stock treasuri promisionari note exchang common capit leas cash provid financ cash equival cash cash cash equival financ market akebia therapeut sec file research estim contact inform robert hazlett manag director btig
btig cover compani mention report
appendix analyst certif import disclosur
